Literature DB >> 8664630

Clinical immunology.

T E Mollnes1, M Harboe.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8664630      PMCID： PMC2351204          DOI： 10.1136/bmj.312.7044.1465

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  36 in total

1.  Aspects of the design and delivery of microparticles for vaccine applications.

Authors:  P G Jenkins; A G Coombes; M K Yeh; N W Thomas; S S Davis
Journal:  J Drug Target       Date:  1995       Impact factor: 5.121

2.  Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

Authors:  J C Magee; B H Collins; R C Harland; B J Lindman; R R Bollinger; M M Frank; J L Platt
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

3.  Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin.

Authors:  I Krause; M Blank; J Kopolovic; A Afek; I Goldberg; Y Tomer; Y Shoenfeld
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

4.  Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1.

Authors:  K S Kilgore; J P Shen; B F Miller; P A Ward; J S Warren
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

Review 5.  Haemophilus influenzae type b conjugate vaccines.

Authors:  P J Kniskern; S Marburg; R W Ellis
Journal:  Pharm Biotechnol       Date:  1995

6.  HCV infection in patients with primary defects of immunoglobulin production.

Authors:  I Quinti; F Pandolfi; R Paganelli; D el Salman; A Giovannetti; R Rosso; A Oliva; L Rainaldi; F Aiuti
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

7.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.

Authors:  K R McCurry; D L Kooyman; C G Alvarado; A H Cotterell; M J Martin; J S Logan; J L Platt
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

8.  Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru.

Authors:  R E Begue; G Castellares; R Ruiz; K E Hayashi; J L Sanchez; E Gotuzzo; R B Oberst; D N Taylor; A M Svennerholm
Journal:  Vaccine       Date:  1995-05       Impact factor: 3.641

9.  Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation.

Authors:  C Gautreau; T Kojima; G Woimant; J Cardoso; P Devillier; D Houssin
Journal:  Transplantation       Date:  1995-11-15       Impact factor: 4.939

10.  Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies.

Authors:  J A LaVecchio; A D Dunne; A S Edge
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.